



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Correspondence

COVID-19: Start with the nose



To the Editor:

We read with interest the data from Jackson et al¹ that revealed lower angiotensin-converting enzyme 2 (ACE2) expression in nasal brushings from children with allergic sensitization, along with a progressive decline in ACE2 expression in relation to increasing IgE sensitization in those with asthma. Moreover, in nasal brushings from adults with allergic rhinitis, ACE2 expression was lower after exposure to cat allergen.

This may be clinically relevant because severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the respiratory epithelium via an endocytic process mediated by ACE2, especially because the nose is usually the first portal of entry for viral infection. The nasopharynx is a common site for SARS-CoV-2 testing. Nasal secretions are swept by rapid nasociliary clearance into the oropharynx and thereby aspirated into the lower respiratory tract, where SARS-CoV-2 causes severe hypoxic pneumonia followed by an associated systemic cytokine-induced autoimmune hyperinflammatory response and coagulopathy.²

Pointedly coronavirus disease-2019 (COVID-19) often presents initially with impaired smell due to involvement of the olfactory nerve endings in the nose. ACE2 expression is highest in the nose, with decreasing levels throughout the respiratory tract, which is mirrored by a gradient of SARS-CoV-2 infection along the airway epithelium.³ The nasal expression of ACE2 also appears to be age dependent, with lower levels in children compared with adults.⁴ Whether or not this might explain the higher prevalence and worse outcomes of COVID-19 in older people remains uncertain.

We believe these observations may be clinically relevant when considering strategies to modify early SARS-CoV-2 infection. One possibility is to suppress replication of SARS-CoV-2 in the nose with topical delivery of antivirals, which would achieve a high local concentration. In a study of experimental coronavirus cold in healthy volunteers, the use of prophylactic treatment with intranasal IFN- α -2b resulted in shortened duration and attenuated severity of symptoms.⁵

Another putative therapeutic strategy might be to use intranasal corticosteroids on a prophylactic basis. The premise is that inhaled corticosteroids are associated with dose-dependent down-regulation of expression of both ACE2 and transmembrane protease, serine 2 in induced sputum from patients with asthma.⁶ Whether the same might occur with intranasal corticosteroids warrants further investigation. Furthermore, there is evidence of a corticosteroid-specific effect with ciclesonide and mometasone, but not fluticasone beclomethasone or budesonide, in terms of suppressing *in vitro* replication of SARS-CoV-2.⁷

For patients with unified allergic airways disease, this reinforces the importance of adhering to both inhaled and intranasal corticosteroid therapy, which will achieve optimal upper and lower airway disease control and may also afford protection against viral triggers including SARS-CoV-2.

We also believe there is also a need to assess whether prophylactic use of intranasal corticosteroid might modify disease progression of COVID-19 in susceptible older individuals with comorbidities, including those in care homes.

Brian Lipworth, MD

Rory Chan, MBChB

Chris RuiWen Kuo, MBChB

From the Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom. E-mail: b.j.lipworth@dundee.ac.uk.

Disclosure of potential conflict of interest: B. J. Lipworth reports grants and personal fees from AstraZeneca, Teva, Chiesi, and Meda; personal fees from Cipla and Glenmark, relevant to the submitted work; personal fees from Lupin and grants and personal fees from Sanofi, outside of the submitted work; and that his son is an employee of AstraZeneca. C. R. Kuo reports personal fees from AstraZeneca and personal fees from Chiesi, relevant to the submitted work. R. Chan reports no relevant conflicts of interest.

REFERENCES

1. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol* 2020;146:203-6.e3.
2. Lipworth B, Chan R, Lipworth S, RuiWen Kuo C. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. *J Allergy Clin Immunol Pract* 2020;8:1798-801.
3. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinno KH III, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *cell* 2020;182:429-46.e14.
4. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. *JAMA* 2020;323:2427-9.
5. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. *J Infect Dis* 1986;154:443-7.
6. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. *Am J Respir Crit Care Med* 2020;202:83-90.
7. Matsuyama S, Kawase M, Nao N, Shirato K, Ujiike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 [published online ahead of print March 12, 2020]. *bioRxiv*. <https://doi.org/10.1101/2020.03.11.987016>.

Available online August 14, 2020.

<https://doi.org/10.1016/j.jaci.2020.06.038>

Reply



To the Editor:

Lipworth et al¹ raise interesting and important concepts related to the central role that the nose plays in susceptibility to respiratory viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The nasal epithelium is the initial target for SARS-CoV-2 infections, and Hou et al² recently demonstrated greater angiotensin-converting enzyme 2 expression and an associated enhanced susceptibility to SARS-CoV-2 infection in upper versus lower airway cells. Furthermore, a progression of infection from the upper to lower airway has been clearly demonstrated for other respiratory viruses. For example, inoculation studies with rhinovirus have shown that there is often a delay of 2 to 4 days from upper to lower airway rhinovirus infection.³ Collectively, these data suggest that targeting the upper airway with prophylactic strategies to prevent infection and/or therapeutic approaches in early infection to avoid progression to the lower airway hold significant promise in impacting coronavirus disease-2019 (COVID-19) susceptibility and disease outcomes.

Lipworth et al suggest that intranasal corticosteroids should be tested for their ability to prevent severe COVID-19. Although intriguing in concept, data to date have been mixed on the impact of